You are here

Our science / Clinical Trials / Find a Trial / NCT00683384

Study Evaluating the Safety of Enbrel (Etanercept)

Back to Search Print Save as PDF Bookmark Trial

NCT00683384

Last updated on October 5, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Metro Manila, , Philippines
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriatic Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0+
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- All patients from the study center who received or will receive at least one dose of
Enbrel according to the approved product indication.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Previously discontinued Enbrel therapy due to significant safety concern.

NCT00683384
Pfizer
Completed
Study Evaluating the Safety of Enbrel (Etanercept)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Osteoarthritis
Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
NCT02674386
All Genders
18+
Years
Multiple Sites
Knee Osteoarthritis, Hip Osteoarthritis
Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee
NCT02697773
All Genders
18+
Years
Multiple Sites
Chronic Pain, Hip Osteoarthritis, Knee Osteoarthritis
Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee
NCT02528188
All Genders
18+
Years
Multiple Sites
Rheumatoid Arthritis
Rheumatoid Arthritis Satisfaction Outcome Research
NCT03703817
All Genders
19+
Years
Multiple Sites
Study Evaluating the Safety of Enbrel (Etanercept)
A Prospective, Observational Study to Monitor Safety in Patients Who Were Administered With Etanercept (Enbrel) 25 mg by Subcutaneous Injection
The purpose of this study is to collect post-marketing information on the safety of Enbrel in Filipino patients.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Primary Care
Arthritis, Psoriatic
Drug: Etanercept (Enbrel)
1
Intervention: Drug: Etanercept (Enbrel)
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
93
October 2009
October 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • All patients from the study center who received or will receive at least one dose of Enbrel according to the approved product indication.

Exclusion Criteria:

  • Previously discontinued Enbrel therapy due to significant safety concern.
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Philippines
United States
 
NCT00683384
0881A-102300
No
Not Provided
Not Provided
Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
October 2010

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now